Mirum Pharmaceuticals MIRM
United StatesHealthcare · BiotechnologyUSD
145.79 USD (+80.8%)
14 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Mirum Pharmaceuticals is a US biotech focused on developing and commercializing treatments for rare liver diseases, with a model combining already approved drugs and a pipeline in advanced clinical stages.
Key points
from its scores- ✓Strong growth9.4
- ✓Favourable backdrop8.0
- ✓Good share-price trend7.2
- ✕Little or no dividend0.5
- ✕Demanding valuation3.0
AI analysis
bottom line, main risk, context and newsGrowth and a clean balance sheet support the thesis, but negative profitability and a demanding valuation require clinical progress before adding positions.
Mirum is growing strongly (revenue +37.9%) and maintains a solid financial position with net cash (ND/EBITDA -4.62) and liquidity of 2.86, though it remains operationally loss-making (margin -14.8%) and its valuation rests on the future success of its pipeline, with an FCF yield of 1.46%.
The risk is failure or delay of a pipeline clinical trial, which would leave the current valuation unsupported given the lack of earnings.
Context and risks
No recent relevant news and no material exposure to current macro factors (rates, oil, tariffs or shipping routes) for a US biotech with net cash. The main risk is its own clinical development, which does not depend on the macro context.
Is Mirum Pharmaceuticals stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 148% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / sales | 8.5 | 3.4 | +148% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.0 out of 10 (median for Healthcare: 4.7).
Average analyst target: 145.79 USD, +80.8% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 5.4 (sector 5.5), Growth 9.4 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −232.6
- EV / EBITDA
- −79.1
- Price / book
- −500.9
- Price / sales
- 8.5
- Market cap
- 5.2B USD
- Enterprise value
- 5.6B USD
Profitability
- ROE
- −703.0%
- ROA
- −6.8%
- Gross margin
- 81.7%
- Operating margin
- −14.8%
- Net margin
- −139.2%
- Free cash flow
- 76.6M USD
- FCF yield
- 1.5%
Solvency
- Total debt
- 762.9M USD
- Net debt
- 324.7M USD
- Cash
- 438.3M USD
- EBITDA
- −70.3M USD
- Net debt / EBITDA
- −4.62
- Current ratio
- 2.86
- Quick ratio
- 2.62
Growth
- Revenue growth
- +37.9%
- EPS (TTM)
- −14.10 USD
- EPS (forward)
- −0.35 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.61
- Analyst consensus
- Strong buy (14)
- Target price
- 145.79 USD
- 52-week range
- 63.23 – 130.00
Recent news
All MIRM news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Mirum Pharmaceuticals
Is Mirum Pharmaceuticals stock cheap or expensive?
On Price / sales, it trades 148% above the Healthcare median. Valuation score: 3.0 out of 10 (median for Healthcare: 4.7). Average analyst target: 145.79 USD, +80.8% versus the price. This is not investment advice.
What score does Mirum Pharmaceuticals get on MeridIAn Screener?
It scores 5.8 out of 10, rank 1,179 of 2,130 (better than 43% of the companies analysed). Its strongest category is Growth (9.4) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Mirum Pharmaceuticals worth on the stock market?
Its market capitalisation is 5.2B USD and its enterprise value, debt included, is 5.6B USD.
How much debt does Mirum Pharmaceuticals have?
Its net debt (debt minus cash) is 324.7M USD.
Does Mirum Pharmaceuticals pay a dividend?
It pays no dividend, or almost none.
How has Mirum Pharmaceuticals stock performed over the last year?
It has risen 10.9% over the last year, excluding dividends. Over the last 52 weeks it has traded between 63.23 and 130.00 USD. Past performance does not guarantee future results.
What do analysts think of Mirum Pharmaceuticals?
14 analysts cover it; their average recommendation is “Strong buy” and their average target is 145.79 USD (+80.8% versus the price). It is an estimate, not market data.